|
[1]ZHOU J,ZHOU F,WANG W,et al.Epidemiological feature of NAFLD from 1999 to 2018 in China[J].Hepatology,2020,75(5):1851-1864.
|
|
[2]ZHOU F,ZHOU J,WANG W,et al.Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018:A systematic review and meta-analysis[J].Hepatology,2019,70(4):1119-1133.
|
|
[3]LONARDO A,NASCIMBENI F,MANTOVANI A,et al.Hypertension,diabetes,atherosclerosis and NASH:Cause or consequence?[J].J Hepatol,2018,68(2):335-352.
|
|
[4]MILLS KT,STEFANESCU A,HE J.The global epidemiology of hypertension[J].Nat Rev Nephrol,2020,16(4):223-237.
|
|
[5]LOPEZ-SUAREZ A,GUERRERO JM,ELVIRA-GONZALEZ J,et al.Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase[J].Eur J Gastroenterol Hepatol,2011,23(11):1011-1017.
|
|
[6]LORBEER R,BAYERL C,AUWETER S,et al.Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease[J].J Hypertens,2017,35(4):737-744.
|
|
[7]ANENT EC,ONI ET,MARTIN SS,et al.Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of card iometabolic risk[J].J Hypertens,2015,33(6):1207-1214.
|
|
[8]FENG RN,DU SS,WANG C,et al.Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population[J].World J Gastroenterol,2014,20(47):17932-17940.
|
|
[9]BONNET F,GASTALDELLI A,PIHAN-LE BARS F,et al.Gamma-glutamyltransferase,fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies[J].J Hypertens,2017,35(3):493-500.
|
|
[10]HUH JH,AHN SV,KOH SB,et al.A prospective study of fatty liver index and incident hypertension:The KoGESARIRANG study[J].PLoS One,2015,10(11):e0143560.
|
|
[11]RYOO JH,SUH YJ,SHIN HC,et al.Clinical association between non-alcoholic fatty liver disease and the development of hypertension[J].J Gastroenterol Hepatol,2014,29(11):1926-1931.
|
|
[12]SUNG KC,WILD SH,BYRNE CD.Development of new fattyliver,or resolution of existing fatty liver,over five years of follow-up,and risk of incident hypertension[J].J Hepatol,2014,60(5):1040-1045.
|
|
[13]QIAN LY,TU JF,DING YH,et al.Association of blood pressure level with nonalcoholic fatty liver disease in nonhypertensive population:Normal is not the new normal[J].Medicine(Baltimore),2016,95(29):e4293.
|
|
[14]WANG Y,ZENG Y,LIN C,et al.Hypertension and non-alcoholic fatty liver disease proven by transient elastography[J].Hepatol Res,2016,46(13):1304-1310.
|
|
[15]MA J,HWANG SJ,PEDLEY A,et al.Bi-directional analysis between fatty liver and cardiovascular disease risk factors[J].J Hepatol,2017,66(2):390-397.
|
|
[16]SORRENTINO P,TERRACCIANO L,D'ANGELO S,et al.Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin,HOMA-IR,and hypertension[J].Am J Gastroenterol,2010,105(2):336-344.
|
|
[17] SINGH S,ALLEN AM,WANG Z,et al.Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis:A systematic review and meta-analysis of paired-biopsy studies[J].Clin Gastroenterol Hepatol,2015,13(4):643-654.
|
|
[18] European Association for the Study of the Liver(EASL);European Association for the Study of Diabetes(EASD);European Association for the Study of Obesity(EASO).EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J].J Hepatol,2016,64(6):1388-1402.
|
|
[19]NAKAMURA M,YAMAZAKI O,SHIRAI A,et al.Preserved Na/HCO3 cotransporter sensitivity to insulin may promote hypertension in metabolic syndrome[J].Kidney Int,2015,87(3):535-542.
|
|
[20]ALAM S,MUSTAFA G,ALAM M,et al.Insulin resistance in development and progression of nonalcoholic fatty liver disease[J].World J Gastrointest Pathophysiol,2016,7(2):211-217.
|
|
[21]KHAN RS,BRIL F,CUSI K,et al.Modulation of insulin resistance in nonalcoholic fatty liver disease[J].Hepatology,2019,70(2):711-724.
|
|
[22]BOLLER S,JOBLIN BA,XU L,et al.From signal transduction to signal interpretation:An alternative model for the molecular function of insulin receptor substrates[J].Arch Physiol Biochem,2012,118(3):148-155.
|
|
[23]GUO S.Insulin signaling,resistance,and the metabolic syndrome:Insights from mouse models into disease mechanisms[J].J Endocrinol,2014,220(2):T1-T23.
|
|
[24]HORITA S,SEKI G,YAMADA H,et al.Insulin resistance,obesity,hypertension,and renal sodium transport[J].Int J Hypertens,2011,2011:391762.
|
|
[25]ARTUNC F,SCHLEICHER E,WEIGERT C,et al.The impact of insulin resistance on the kidney and vasculature[J].Nat Rev Nephrol,2016,12(12):721-737.
|
|
[26]MINEMURA M,SHIMIZU Y.Gut microbiota and liver diseases[J].World J Gastroenterol,2015,21(6):1691-1702.
|
|
[27]JI Y,YIN Y,LI Z,et al.Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease(NAFLD)[J].Nutrients,2019,11(8):1712.
|
|
[28]MARQUES FZ,MACKAY CR,KAYE DM.Beyond gut feelings:How the gut microbiota regulates blood pressure[J].Nat Rev Cardiol,2018,15(1):20-32.
|
|
[29]LEUNG C,RIVERA L,FURNESS JB,et al.The role of the gutmicrobiota in NAFLD[J].Nat Rev Gastroenterol Hepatol,2016,13(7):412-425.
|
|
[30]KANG Y,CAI Y.Gut microbiota and hypertension:From pathogenesis to new therapeutic strategies[J].Clin Res Hepatol Gastroenterol,2018,42(2):110-117.
|
|
[31]TE RIET L,van ESCH JH,ROKS AJ,et al.Hypertension:Renin-angiotensin-aldosterone system alterations[J].Circ Res,2015,116(6):960-975.
|
|
[32]PASCHOS P,TZIOMALOS K.Nonalcoholic fatty liver disease and the renin-angiotensin system:Implications for treatment[J].World J Hepatol,2012,4(12):327-331.
|
|
[33]MATTHEW MORRIS E,FLETCHER JA,THYFAULT JP,et al.The role of angiotensin II in nonalcoholic steatohepatitis[J].Mol Cell Endocrinol,2013,378(1-2):29-40.
|
|
[34]WU Y,MA KL,ZHANG Y,et al.Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease[J].Liver Int,2016,36(10):1525-1534.
|
|
[35]TOBLLI JE,MUNOZ MC,CAO G,et al.ACE inhibition and AT1receptor blockade prevent fatty liver and fibrosis in obese Zucker rats[J].Obesity(Silver Spring),2008,16(4):770-776.
|
|
[36]POLYZOS SA,KOUNTOURAS J,MANTZOROS CS,et al.Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance,non-invasive indices of steatosis and fibrosis,and adipokine levels in non-alcoholic fatty liver disease:A randomized controlled trial[J].Diabetes Obes Metab,2017,19(12):1805-1809.
|
|
[37]YOKOHAMA S,YONEDA M,HANEDA M,et al.Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis[J].Hepatology,2004,40(5):1222-1225.
|
|
[38]GEORGESCU EF,IONESCU R,NICULESCU M,et al.Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis[J].World J Gastroenterol,2009,15(8):942-954.
|
|
[39]MILIC S,MIKOLASEVIC I,KRZNARIC-ZRNIC I,et al.Nonalcoholic steatohepatitis:emerging targeted therapies to optimize treatment options[J].Drug Des Devel Ther,2015,9:4835-4845.
|
|
[40]MCPHERSON S,WILKINSON N,TINIAKOS D,et al.A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis[J].PLoS One,2017,12(4):e0175717.
|
DownLoad: